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IFAPP (International Federation of Associations of Pharmaceutical Physicians and
Pharmaceutical Medicine) is a nonprofit organization with the mission to promote
Pharmaceutical Medicine & Medicines Development (PM&MD) by enhancing the
competencies and maintaining high research ethical standards of Pharmaceutical
Physicians and other professionals involved in medicines development worldwide,
leading to the availability and appropriate use of medicines for the benefit of patients
and society1. About 30 national professional associations related to PM&MD, involving
7000 professionals, are affiliated to IFAPP. Medicines development has traditionally been
a challenging enterprise, with high risk, high investment, and potentially high returns in
the lengthy and complex process of identifying a new chemical entity as a candidate
for development and possibly succeeding in bringing it as a pharmaceutical product to
the market. However, the emergence of genomics, translational research, biomarkers,
and precision medicine pose challenges going forward involving allocation of resources,
price, market access, and cost-effectiveness as opposed to the traditional concepts of
“efficacy” and “safety.” Education and Continuing Professional Development (CPD) are a
major focus of IFAPP. The International Conference on Pharmaceutical Medicine (ICPM)
is the largest event for our organization; ICPM is held every 2 or 3 years and is aimed to
provide the state of the art in key areas for our discipline and profession. The paper is
a reflection on the role of competency-based education and training for Pharmaceutical
Physicians and medicines development scientists, as was discussed during the recent
ICPM 2016 held in Sao Paulo, Brazil on April 18–19, with the support of the Brazilian
Association of Pharmaceutical Medicine, and gathered around 200 representatives from
the pharmaceutical, clinical research and regulatory arenas from all over the world2,3.
Keywords: competencies, certification, patient outcomes, medical affairs, outcomes based education, patient
centricity, ethics
1IFAPP. Available at: www.ifapp.org (Accessed latest; 22 September, 2016).
2ICPM 2016. Available at: http://www.icpm2016.com/en/programacao/programa (Accessed latest; 22 September, 2016).
3Brazilian Association of Pharmaceutical Medicine. Available at: http://www.sbmf.org.br (Accessed latest; 22 September,
2016).
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INTRODUCTION
Pharmaceutical medicine is defined by the Faculty of
Pharmaceutical Medicine as “the medical scientific discipline
concerned with the discovery, development, evaluation,
registration, monitoring, and medical aspects of marketing
of medicines for the benefit of patients and the health of the
community4.”
The discipline involves several traditional professions and
activities, such as medicine, pharmacy, clinical pharmacology,
pharmaceutical sciences biology, etc. Therefore, the terms
Pharmaceutical Physicians (PPs) and Medicines Development
Scientists (MDS) refer to individuals with different academic
backgrounds working in similar fields.
The latter term refers to experts who are not medically
qualified, work in various fields of natural sciences, pharmacy,
and medical device engineering, have adequate training in non-
clinical and clinical aspects of medicines development and work
as integrated members of clinical medicines development teams.
Pharmaceutical Medicine and Medicines Development are thus
evolving into integrated concepts.
“At core of the discipline is: the clinical testing of medicines,
translation of pharmaceutical drug research into new medicines,
safety and well-being of research participants in clinical trials,
understanding the safety profile of medicines and their benefit-
risk balance4.”
These are the core domains of Pharmaceutical Medicine
and Medicines Development. “In addition to expertise in the
science of drug development PPs and MDS need a thorough
understanding of pharmacoeconomics, medical aspects of the
marketing of medicines, medical affairs, business administration,
and the social impact of healthcare on patients and public
health. PPs and MDS work in the pharmaceutical industry, drug
regulatory authorities and contract research organizations, but
have a close affinity with their medical colleagues in primary and
secondary health care and at universities4.”
Two recent trends—one in drug development and one in
drug regulation—are reinforcing the importance of earlier drug
evaluation and the conduct of clinical trials. In recent years
the pharmaceutical industry has showed a growing interest in
developing drugs for niche markets. The narrow population base
for these therapies often inherently limits the amount of safety
and efficacy data available to support the traditional regulatory
approval, which underscores the importance of assessing the
benefits and risks of these new drugs through the ongoing
collection and analysis of post-marketing surveillance data and
comparative effectiveness studies. The criteria for efficacy and
safety of new medicines are evolving continuously and are
discussed regularly in scientific fora.
As a professional organization IFAPP has been actively
involved in creating awareness and fostering education and
training in the following areas: Competencies and Competency
Based Education; Patient Centricity and Patient-Reported
Outcomes Measures (PROMs); Certification and Specialization;
4Adapted from “What is Pharmaceutical Medicine?” Available at:
https://www.fpm.org.uk/aboutus/whatispharmamed (Accessed latest; 22
September, 2016).
the emerging role of Medical Affairs and the need for an ethical
framework in the practice of Pharmaceutical Medicine.
COMPETENCIES AND COMPETENCY
BASED EDUCATION
Medicines Development has become a compartmentalized and
segmented activity and gradually the focus is on education and
training for the individual compartments or domains described
above (safety, regulatory, clinical research, medical affairs, health
outcomes, etc). However, the principles of Pharmaceutical
Medicine as a discipline and a professional activity are
fundamental to ensure a proper balance in meeting the needs
of the health-care system, the patient, the regulatory agencies,
and the pharmaceutical industry. Therefore, a professional
involved in medicines development should be able to master the
competencies needed for an effective performance.
Competencies refer to the “observable ability of a health
professional integrating knowledge, skills, values and attitudes”
to perform effectively. Competencies are the ingredients of
Competence. A competent professional is the one possessing
the required abilities (competencies) in all domains in a certain
context at a defined stage of education or practice. The
progression of competence, from novice to mastery, can be also
defined (Frank et al., 2010).
IFAPP and PharmaTrain created a working group including
representatives from either institution, with special interest and
experience on quality improvement through education. As a
result a basic set of 7 domains and 57 competencies and
a Statement of Competence were defined (Silva et al., 2013,
Table 1). The competencies were aligned with the learning
outcomes of the base course offered by PharmaTrain5 and thus a
standard for competency-based education (at the cognitive level)
could be used for certification of the IFAPP membership.
More recently, another working group developed the full set
of applied knowledge, skills, behaviors and attitudes for each
competency and a process for internal and external validation
was initiated6. The full core competencies are the foundation
for the curriculum of the Specialist in Medicines Development,
one of the certification programs developed in collaboration with
PharmaTrain.
IFAPP representatives have also been involved in the
definition and validation of core competencies in clinical research
(Sonstein et al., 2014, in press).
The competencies are intended to be used as a resource
and guide to improve the quality and accountability of
Pharmaceutical Medicine education and training (Sonstein et al.,
2014,Table 2). Themodelmay foster further granularity and thus
specific sub-competencies and specialty competencies that apply
to specific functions in clinical research and drug development
could be identified. The primary vision for this competency
model is the availability of professionals more fully prepared
5PharmaTrain. Available at: https://www.imi.europa.eu/content/pharmatrain
(Accessed latest; 22 September, 2016).
6IFAPP: Core Competencies in Pharmaceutical Medicine and Medicines
Development. Available at: http://ifapp.org/Education/Publication-on-education
(Accessed latest; 22 September, 2016).
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TABLE 1 | Statement of Competence*.
STATEMENT OF COMPETENCE
The Pharmaceutical Physician/Medicines Development Scientist:
• Is able to identify unmet therapeutic needs, evaluate the evidence for a new candidate for clinical development and design a Clinical Development Plan for a Target
Product Profile.
• Is able to design, execute and evaluate exploratory and confirmatory clinical trials and prepare manuscripts or reports for publication and regulatory submissions.
• Is able to interpret effectively the regulatory requirements for the clinical development of a new drug throughout the product life-cycle to ensure its appropriate
therapeutic use and proper risk management.
• Is able to evaluate the choice, application and analysis of post-authorization surveillance methods to meet the requirements of national/international agencies for
proper information and risk minimization to patients and clinical trial participants.
• Is able to combine the principles of clinical research and business ethics for the conduct of clinical trials and commercial operations within the organization.
• Is able to appraise the pharmaceutical business activities in the healthcare environment to ensure that they remain appropriate, ethical and legal to keep the welfare
of patients and research participants at the forefront of decision-making in the promotion of medicines and design of clinical trials.
• Is able to interpret the principles and practices of people management and leadership, using effective communication techniques and interpersonal skills to influence
key stakeholders and achieve the scientific and business objectives.
*Adapted from Silva et al. (2013).
TABLE 2 | Potential Use of Professional Competencies in the creation of
standards*.
• Curriculum development
• Training initiatives
• Basic training requirements
• Guidance for job descriptions and job portfolios
• Defining professional careers and pathways
• Performance evaluations
• Policy Development
• Regulatory Compliance
• Quality Improvement
• Accreditation of academic programs
• Professional Certification
• Performance across the medicines development chain
*Adapted from Sonstein et al. (2014).
for the many challenges and opportunities in Pharmaceutical
Medicine in the next decade.
We intend to use the core competencies to define profiles
of key functions in medicines development. Standardized job
descriptions for various roles could be developed globally to
reassure every stakeholder that the processes related to medicines
development are in the hands of competent biomedical
professionals.
Competency models are iterative processes, and our model
will have to be regularly updated as the competencies are
deployed and used for professional, academic or self-assessment
purposes and the business and scientific environment change.
THE EXAMPLE OF PATIENT-REPORTED
OUTCOMES MEASUREMENT
The use of Patient-Reported Outcomes Measures (PROMs) is
a growing emerging trend and challenge in clinical research.
PROMs are particularly important in clinical trials because they
are the only measure that directly reflects the patient’s own
perspective on the impact of treatment on health and disease.
Measuring the impact of new treatments on Health-Related
Quality of Life (HRQL) in clinical trials is particularly important,
adding a unique and highly relevant perspective on efficacy as
perceived by the patient (Acquadro et al., 2003).
Thanks to an increasing interest in the patient perspective,
HRQL questionnaires are nowadays frequently used and
considered important by investigators, registration bodies, health
authorities, and health technology assessment officers.
Disease specific questionnaires for new treatment indications
and/or orphan diseases are the ones that create a problem
given the financial hurdles and proprietary issues related to new
assessment tools. Small start-up companies might be particularly
affected because of their limited resources and expertise in HRQL
matters.
Measuring HRQL is complex. As recommended by the FDA,
the first step in the selection of a HRQLmeasurement instrument
is to develop a conceptual framework based on the concepts
of interest for measuring meaningful treatment benefit to the
patient, and to determine the intended population for the clinical
trial. The second step consists of developing an endpoint model
identifying the relationship among clinical and patient-based
outcomes of interest7. This will provide the basis for identifying
or adapting available validated questionnaires that measure the
concept(s) of interest in the context of use. If no suitable
questionnaires are identified, for example in a new therapeutic
area, it may be necessary to develop a new questionnaire,
adding to the complexity, time, and cost of including HRQL
measures.
Clinical trials involving patients with rare diseases are
particularly challenging for the selection, implementation, and
interpretation of PROMs. This is mainly due to the small number
7FDA Clinical Outcome Assessment Qualification Program.
Available at: http://www.fda.gov/drugs/developmentapprovalprocess/
drugdevelopmenttoolsqualificationprogram/ucm284077.htm (Accessed latest; 22
September 2016).
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of patients usually included and the high heterogeneity of the
patient populations8.
The increasing use of electronic versions of PRO
questionnaires instead of paper and pencil administration
may help to reduce the time spent for questionnaire completion
and data collection, but adds further to the cost and complexity of
validating this mode of administration. The linguistic validation
procedures for demonstrating cross-cultural validity add further
complexity when including PROs in multi-country studies.
Unfortunately, HRQL assessments are often of poor quality
(Martini et al., 2016), despite many guidelines9,10. In the domain
of cancer, this has led the American Society of Clinical Oncology
(ASCO) to excluding HRQL from its conceptual framework to
assess the value of new options for cancer treatment (Schnipper
et al., 2015, 2016)11.
The importance of abiding by scientific methods and
guidelines in conducting and reporting HRQL studies and
the increasing complexity of selecting and developing new
questionnaires has prompted IFAPP to include HRQL in the
Competence in Medicines Development topics which would
serve as the basis to develop specific education and training
programs aimed to foster the proper application of guidelines and
publishing PRO results.
FOSTERING THE EMERGING ROLE OF
MEDICAL AFFAIRS
Medical Affairs organizations have emerged over the past half
century in response to federal regulations around the separation
of medical and commercial activities within drug companies.
They aim to provide patient and physician centered services
as part of a new business model aimed to provide value in
healthcare. Many companies also chose to focus R&D resources
on developing new products and moved post-launch activities,
such as finding new indications for existing drugs, into the
Medical Affairs function.
Continued pressures from regulatory agencies and public
sentiment have pushed more and more activities into Medical
Affairs organizations. Today, these organizations commonly
involve the following medical activities:
- Medical education
8Clinical Outcome Assessment (COA) in Rare Disease Clinical Trials -
Emerging Good Practices: Report of the ISPOR Rare Disease Trials COA
Measurement Task Force. Available at: http://www.ispor.org/TaskForces/
COA_Measurement_RareDiseases_2016DC_forum.pdf (Accessed latest; 22
September, 2016).
9EMEA Reflection paper on the regulatory guidance for the use of Health-Related
Quality of Life (HRQL) measures in the evaluation of medicinal products.
Available at: http://www.ema.europa.eu/docs/en_GB/document_library/
Scientific_guideline/2009/09/WC500003637.pdf (Accessed latest; 21 September,
2016).
10EMA Appendix 2 to the guideline on the evaluation of anticancer
medicinal products in man. The use of patient-reported outcome (PRO)
measures in oncology studies. Available at: http://www.ema.europa.eu/docs/
en_GB/document_library/Other/2016/04/WC500205159.pdf (Accessed latest; 21
September, 2016).
11ASCO Value Framework Update Statement by ASCO President Julie M. Vose,
MD, MBA, FASCO, May 31, 2016. Available at: http://www.asco.org/advocacy-
policy/asco-in-action/asco-value-framework-update (Accessed latest; 17 August,
2016).
- Medical field teams
- Post-launch clinical trials
- Medical-information services
- Medical communications
- Medical strategic activities
- Medical grants
- Publications
- Health Economics and Outcomes Research
These functions make relevant contributions in the decision
making process among key medical stakeholders and customers
by facilitating coordination and integration of medical data and
knowledge.
A special session related to “The future of Medical Affairs
organizations in pharmaceutical companies” was held during
ICPM 2016 and key executives from the Medical Departments
from major pharmaceutical companies were invited to discuss
the needs for the development and evolution of Medical Affairs
departments within pharmaceuticals, to share their vision and
expectations as senior medical leaders for their organizations
in order to provide patient and physician centered services
for improved health care and to discuss the challenges and
opportunities to leveraging the reputation and credibility of the
industry in public opinion.
Panelists discussed and concurred that physicians and other
professionals who serve in the Medical Affairs areas are
positioned at a dynamic and critically important interface
between the biopharmaceutical industry and the medical
community. Their role is to communicate data-driven findings
to the medical world while obtaining input from physicians
and leaders in medicine about clinical issues and the direction
that medicine is taking. They also highlighted that the medical
interface between a healthcare company and the practice of
medicine—the physician-to-physician interface with a culture
based on the proper practice of medicine is at the root of
a successful medical affairs organization. All these companies
confirmed that their Medical Affairs organization consists of
individuals who take an external focus, provide an outside-in
perspective, and possess the ability to influence internally and has
a growing importance in places where the role of the physician is
evolving in healthcare (away from business/purchasing focus and
into advocacy as part of larger systems).
As an outlook for the future, the panelists agree many
companies are fostering the creation and further development
of Medical Affairs Units in their structure, aiming to strengthen
the peer-to-peer communication and building credible expertise
in local healthcare networks/systems instead of the usual
commercial approach of just “promotion of” pharmaceuticals.
Several examples of biased medical information have been cited
in the past few years. The withholding of product information
that may affect the overall profile of efficacy and safety for
any product may have a significant negative impact among all
stakeholders, particularly patients, and the regulatory agencies,
and affects the overall reputation of the industry (Cohen, 2014)12.
12Dave D. Effects of Pharmaceutical Promotion. A review and assessment. NBER
Working Paper NO. 18830. February 2013. Available at: http://www.nber.org/
papers/w18830 (Accessed latest; 21 September, 2016).
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Critically important to the success and contributions for the
future ofMedical Affairs organizations will be the proper training
in the sciences fundamental to medicine and the principles
of Medical Affairs as a discipline. There was consensus that
education and training of biomedical personnel have become
a critical need within pharmaceuticals and therefore competent
professionals are needed.
PROFESSIONAL CERTIFICATION AND
SPECIALIZATION
Professional certification, often called simply certification or
qualification, is a designation earned by a person to assure
qualification to perform a job or task. Certification does not
refer to the state of legally being able to practice or work in a
profession. That is licensure. Usually, licensure is administered
by a governmental entity for public protection purposes and
a professional association administers certification. Licensure
and certification are similar in that they both require the
demonstration of a certain level of knowledge or ability. However,
certification is a pre-requisite for licensure. Specialization is a type
of certification, usually required for licensure.
Although fostering the development and international
recognition of Pharmaceutical Medicine as a separate medical
specialty has been one of the key goals for IFAPP since its
inception, the objective has been only partially met. A number of
possible explanations (not enough advocates, lack of awareness
on the discipline among the country decision makers, no
established need for licensure, limited recognition to newmedical
specialties at the country level, etc.) can be attributed to such lack
of success.
Since the certification is granted by the profession, the
appropriate professional certifying bodies would be IFAPP and
PharmaTrain, and because of their global nature would provide
the required international scope.
IFAPP (in collaboration with PharmaTrain and academic
institutions) is entitled to provide professional certification to
its membership, in a two-step process as separate programs
to attest the new competency-based standards for professionals
involved in medicines development. A basic certification (based
upon knowledge) and a vocational certification (based in
competencies) are being developed.
Knowledge Based Certification
This is the theoretical/cognitive competency part of the SMD
program, offered via online CPD in strategic alliance with
academic institutions. The cognitive contents are included
in 6 modules, with a high level of interactivity, which can
be completed in a 6–12 month period. Assessments will be
conducted at the end of each module and a Certificate on
Medical Affairs and Clinical Development should be granted to
students completing the 6 modules. The production of the e-
learning content is planned to be completed in 2016 so that the
Certification of the IFAPP membership may start in 2017 and the
first cohort of certified professionals can be expected in 2018.
Vocational Specialization Program
The Specialist in Medicines Development (SMD) is a
competency-based workplace-centered 2- to 4-year education
and training program, comprising a knowledge based covering
the PharmaTrain syllabus achieved through IFAPP/PharmaTrain
accredited graduate programs in Pharmaceutical Medicine or
its equivalent (the above mentioned Certificate Program on
Medical Affairs and Clinical Development). Participants in
this mentored program acquire competencies within a frame
work of assessment, appraisal, and annual review of progress
and achievement. On completion, participants achieve the
Specialist in Medicines Development awarded by both IFAPP
and PharmaTrain. Pilot experiences have started in Italy and
Japan.
IFAPP will continue its efforts to foster Pharmaceutical
Medicine/Medicines Development as an independent scientific
medical discipline and as a viable and rewarding professional
path for biomedical graduates. It is our goal for the coming years.
ETHICAL FRAMEWORK FOR
PROFESSIONALS INVOLVED IN
MEDICINES DEVELOPMENT
The new technologies, molecular biology, translation medicine,
advanced therapies, medical device-drug combinations, etc.
made the development of medicines much more complex. The
traditional approach focusing almost exclusively on the role of
the physicians having a combined training of pharmacology
and therapeutics, frequently referred to as PPs or clinical
pharmacologists in the different countries, was gradually
replaced by complex clinical investigator teams. Many of these
technologies can be applied only by basic scientists who
frequently are not medically qualified. Nevertheless, their role
can be crucial in making decisions critically influencing the
conduct of studies and clinical trials, and the well-being of the
volunteer research participants. These changes made it necessary
to reconsider the ethical concepts underlying clinical trials.
The ethical ideas formulated by the Faculty of Pharmaceutical
Medicine of the Royal Colleges of Physicians of the UK (The
Faculty) and those by IFAPP were presented at the ICPM
2016 plenary session entitled “Ethics in Medicines Development:
where we stand and were we go.” It is interesting to note
that the two sets of ethical recommendations are conceptually
different, nevertheless, mutually supportive. The target audience
of the Faculty recommendations are the PPs whilst the IFAPP
recommendations consider equally the PPs as well as the MDS
involved.
The Faculty document entitled Good Pharmaceutical Medical
Practice (GPMP) published on 12th November 2014 is essentially
an expanded version of the UK General Medical Council’s Good
Medical Practice13. The Faculty’s intention is to use GPMP as
an adjunct to GMP in the revalidation process of PPs working
in the United Kingdom. Nevertheless, in the introduction of the
13Faculty of Pharmaceutical Medicine. Good Pharmaceutical Medical Practice
(GPMP). Available at: https://www.fpm.org.uk/policypublications/GPMP
(Accessed latest; 21 September, 2016).
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document the authors stated that the recommendations “provide
all doctors around the world specific guidance and direction on
expected standards, conduct and behavior” in drug development.
Since addressees of the document are exclusively PPs it is only
briefly mentioned that decisions are frequently made by a team
and the PPs must be prepared to explain and justify their
specific contribution to decisions that may affect the safety and
well-being of patients. A GPMP Support Network was created
for advising PPs facing ethical or medical dilemmas in their
work.
IFAPP published its International Code of Ethical Conduct
for PPs in 200314,15. Since that time, the membership of IFAPP
has undergone major changes due to the influx of many basic
scientists. These scientifically qualified experts make up now
close to half of the membership. It was recognized that MDS
play increasingly important roles not only by providing scientific
and methodological expertise for the projects but also as active
decision making members of the clinical investigator teams.
Therefore, it was decided to reconsider the guiding concept of the
original document and address the ethical issues jointly of both
the PPs and the MDS. Accordingly, the title of the document was
also changed to “IFAPP International Ethics Framework for PPs
and Medicines Development Scientists16.”
It is argued that due to the joint participation of PPs and
MDS in decision making concerning for example the selection of
appropriate biomarkers, laboratory methods, the determination
of the amount of biological sample needed, the production of
personalized biological, or advanced medicines, etc., the ethical
responsibilities have to be shared. In addition, it must be
ensured that all the investigations applied in the development of
medicines should be carried out according to the strict quality
standards accepted for the clinical development of medicines
which are more stringent than those traditionally accepted in
basic research. In spite of the close cooperation and joint
14International Federation of Associations of Pharmaceutical Physicians (IFAPP)
International Code of Ethical Conduct for Pharmaceutical Physicians. Available at:
http://ifapp.org/upload/file/Final-Ethics-Code-April-2003.pdf (Accessed latest;
21 September, 2016).
15Becker S, Barrett J, Botha JJ, Caird D, Carlesi R, Jekunen A on behalf of
the IFAPP Working Party on Ethics in Pharmaceutical Medicine. A Proposed
International Code of Ethical Conduct for Pharmaceutical Physicians. Available
at: http://ifapp.org/upload/file/finalpostercancun-s_becker.pdf (Accessed latest; 21
September, 2016).
16IFAPP International Ethics Framework for Pharmaceutical Physicians and
Medicines Development Scientists.” Available at: http://ifapp.org/Ethics (Accessed
latest; 22 September, 2016).
ethical responsibilities, it is emphasized that the supervision
of the well-being of the clinical trial participants remains the
exclusive responsibility of a qualified physician participating in
the development team. The situation is, however, quite complex
since the differently trained members of the development team
might have different ethical priorities under various situations.
Therefore, it was considered to be inappropriate to define
strict ethical guidelines. It was the firm belief of the revising
committee that a framework of advices on correct ethical
behaviors and appropriate actions under selected circumstances
is a more practical support for teams developing complex
medicines.
During the discussion it was emphasized that the two
documents should be used jointly since they emphasize different
but equally important aspects ofmodernmedicines development.
It is planned to publish the two documents side by side, thus
underlying the need for their joint application in medicines
development.
FUTURE DIRECTIONS
As a professional organization IFAPP is committed to foster the
development of key areas for the discipline of Pharmaceutical
Medicine and the profession of Medicines Development in
order to ensure patients and the society at large that the
medicines development process is conducted by competent
individuals.
Competency-based education is now a paradigm for
undergraduate, postgraduate and continuing professional
development and poses another continuing challenge to
the academic institutions and professional associations for
development and assessment of education and training
programs.
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